Algernon Pharmaceuticals Inc. (AGNPF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.98 Million CAD | 38.64% |
| 2022 | -5.94 Million CAD | 26.12% |
| 2021 | - CAD | 7.97% |
| 2020 | -8.42 Million CAD | -360.82% |
| 2019 | -1.89 Million CAD | -109.18% |
| 2018 | -858.18 Thousand CAD | -3.31% |
| 2017 | -1.26 Million CAD | 69.56% |
| 2016 | -2.76 Million CAD | -498638.51% |
| 2015 | 579.00 CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -996.57 Thousand CAD | -93.68% |
| 2024 Q3 | -459.58 Thousand CAD | 56.23% |
| 2024 Q1 | -514.54 Thousand CAD | 47.09% |
| 2023 Q1 | -1.86 Million CAD | 14.65% |
| 2023 Q4 | -972.5 Thousand CAD | 12.8% |
| 2023 FY | - CAD | 38.64% |
| 2023 Q3 | -1.11 Million CAD | 9.72% |
| 2023 Q2 | -1.23 Million CAD | 33.89% |
| 2022 Q1 | -1.2 Million CAD | -119.95% |
| 2022 Q4 | -2.18 Million CAD | -173.93% |
| 2022 Q3 | -799.2 Thousand CAD | 56.38% |
| 2022 Q2 | -1.83 Million CAD | -52.54% |
| 2022 FY | - CAD | 26.12% |
| 2021 Q4 | -546.03 Thousand CAD | 67.43% |
| 2021 Q3 | -1.67 Million CAD | 29.81% |
| 2021 FY | - CAD | 7.97% |
| 2021 Q2 | -2.38 Million CAD | 30.59% |
| 2021 Q1 | -3.44 Million CAD | -20.36% |
| 2020 Q2 | -795.14 Thousand CAD | -129.57% |
| 2020 FY | - CAD | -360.82% |
| 2020 Q3 | -4.6 Million CAD | -479.11% |
| 2020 Q4 | -2.85 Million CAD | 37.92% |
| 2020 Q1 | -346.36 Thousand CAD | 18.74% |
| 2019 Q4 | -426.25 Thousand CAD | 19.07% |
| 2019 Q2 | -440.88 Thousand CAD | 13.78% |
| 2019 Q1 | -511.36 Thousand CAD | -178.49% |
| 2019 FY | - CAD | -109.18% |
| 2019 Q3 | -526.67 Thousand CAD | -19.46% |
| 2018 Q1 | -186.09 Thousand CAD | 34.49% |
| 2018 FY | - CAD | -3.31% |
| 2018 Q4 | -183.62 Thousand CAD | 52.58% |
| 2018 Q3 | -387.2 Thousand CAD | -156.97% |
| 2018 Q2 | -150.68 Thousand CAD | 19.03% |
| 2017 Q3 | 162.36 Thousand CAD | 156.59% |
| 2017 FY | - CAD | 69.56% |
| 2017 Q4 | -284.05 Thousand CAD | -274.95% |
| 2017 Q1 | -469.94 Thousand CAD | -104.35% |
| 2017 Q2 | -286.9 Thousand CAD | 38.95% |
| 2016 Q1 | 3.78 Million CAD | 724339.39% |
| 2016 Q4 | -229.97 Thousand CAD | 51.33% |
| 2016 Q3 | -472.51 Thousand CAD | 76.65% |
| 2016 Q2 | -2.02 Million CAD | -153.4% |
| 2016 FY | - CAD | -498638.51% |
| 2015 Q3 | -203.79 Thousand CAD | 0.0% |
| 2015 Q4 | 523.00 CAD | 100.26% |
| 2015 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 92.987% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 15.98% |
| SQZ Biotechnologies Company | -64.14 Million USD | 92.234% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 71.321% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 105.297% |
| Mesoblast Limited | -62.38 Million USD | 92.016% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -224.303% |
| Genus plc | 73.7 Million USD | 106.759% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 24.655% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -40.442% |
| Marizyme, Inc. | -34.28 Million USD | 85.469% |
| ContraFect Corporation | -64.99 Million USD | 92.336% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 43.212% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -10.058% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -255.36% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -88.374% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -114.365% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -861.586% |
| Accustem Sciences Inc. | -3.74 Million USD | -32.966% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 89.671% |
| EV Biologics, Inc. | -1.26 Million USD | -293.129% |
| Q BioMed Inc. | -617.62 Thousand USD | -706.547% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 239.459% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -687.7% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -118.056% |
| Biomind Labs Inc. | -1.03 Million USD | -381.51% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 150.435% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 30.439% |
| Skye Bioscience, Inc. | -13.54 Million USD | 63.23% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -234.908% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -19825.836% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -28.245% |
| IMV Inc. | -35.52 Million USD | 85.977% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 68.61% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -99.102% |
| GB Sciences, Inc. | -1.41 Million USD | -250.835% |
| Alpha Cognition Inc. | -9.7 Million USD | 48.674% |
| HST Global, Inc. | -5303.00 USD | -93836.621% |
| CSL Limited | 4.78 Billion USD | 100.104% |
| Halberd Corporation | -74.27 Thousand USD | -6606.416% |
| Enzolytics Inc. | -2.12 Million USD | -134.75% |
| Resverlogix Corp. | -11.74 Million USD | 57.576% |
| Affymax, Inc. | -14.29 Million USD | 65.152% |
| SYBLEU INC | -141.57 Thousand USD | -3418.7% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -62.632% |
| argenx SE | -216.02 Million USD | 97.694% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 90.998% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 509.323% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -232.34% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 1414.91% |
| AVAX Technologies, Inc. | -6.11 Million USD | 18.506% |
| Zenith Capital Corp. | -8.6 Million USD | 42.116% |
| Genscript Biotech Corporation | -248.71 Million USD | 97.997% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -28494.564% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -103.619% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -2729.983% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 87.432% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -72.23% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -376.097% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 74184.756% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -184.655% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -159.328% |
| BioStem Technologies, Inc. | -7.55 Million USD | 34.052% |
| ONE Bio Corp. | 13.61 Million USD | 136.593% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -2650.85% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -142.171% |
| Agentix Corp. | -1.37 Million USD | -263.145% |
| LadRx Corporation | 412.28 Thousand USD | 1308.262% |
| Cell Source, Inc. | -4.27 Million USD | -16.593% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -1256.529% |
| Regen BioPharma, Inc. | 1.46 Million USD | 439.81% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -431.668% |
| NovAccess Global Inc. | -1.03 Million USD | -381.395% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 156.264% |
| Itoco Inc. | -1.86 Million USD | -166.531% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -1212.222% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -346.367% |
| Kadimastem Ltd | -2.62 Million USD | -89.815% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -1982.985% |
| CytoDyn Inc. | -18.02 Million USD | 72.37% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -6203.33% |
| Mobile Lads Corp. | -2.24 Million USD | -122.272% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -40634.803% |
| Qrons Inc. | -40.08 Thousand USD | -12328.48% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -925.671% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1044.472% |
| Rebus Holdings, Inc. | -951 Thousand USD | -423.813% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -369.06% |
| International Stem Cell Corporation | 202 Thousand USD | 2566.069% |
| Bioxytran, Inc. | -3.82 Million USD | -30.4% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -9363.258% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -102.339% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 86.112% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -10969.909% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -81.938% |
| Neutra Corp. | -181.24 Thousand USD | -2648.437% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 75.289% |
| PureTech Health plc | -11.62 Million USD | 57.156% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 75.287% |
| IXICO plc | -707 Thousand USD | -604.591% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 35.179% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 89.696% |
| CSL Limited | 4.73 Billion USD | 100.105% |
| Cellectis S.A. | -92.63 Million USD | 94.623% |